IPOTracker
eToroTrade IPO stocks the day they listStart on eToro
All companies
Kailera Therapeutics Inc logo

Kailera Therapeutics Inc

KLRA
PublicArchived
Public / ArchivedUnited StatesUSUnited States(NASDAQ Global Select)Best valuation $2.44BSince IPO +17.94%1 market

Public listing

Listed· NASDAQ Global Select· Listing market: United StatesUS United States
Listing date
Apr 17, 2026
Final IPO price
$16.00
Shares offered
39,062,500
Offering proceeds
$625M

Sources: sec-harvest, nasdaq

IPO Calendar
IPO Calendar · NASDAQIPO
KLRA
Price
$18.87
24h
+3.85%
Valuation
$2.44B
24h volume
$3.37M
Type
IPO
IPO CalendarTrade Kailera Therapeutics Inc

Now trading publicly. Buy via a broker — opens in a new tab.

Trade on IPO Calendar

IPO Calendar · updated 1h ago

Kailera Therapeutics Inc IPO unlock schedule & public float

Lock-up schedule, public float and locked shares extracted from Kailera Therapeutics Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.

424B4Apr 17, 2026
Total shares (FD)
123.68M
Public float
39.06M
Locked
84.62M
IPO raise
$625M
Next unlock
Oct 14, 2026 · 84.62M
Shares eligible to trade · by holder groupApr 17, 2026 → Oct 14, 2026 · 100% unlocked
  • Lock-up holders84.62M
  • IPO public float39.06M
Supply pressure · next 90 daysMedium

Up to 84.62M shares (~2.2× the current float) become eligible within 90 days. A meaningful slice of locked shares becomes eligible within 90 days.

About Kailera Therapeutics Inc

Kailera Therapeutics Inc is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.

What the company does

  • Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
  • Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
  • Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.

Business profile

Kailera Therapeutics Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.

SEC IPO filings

Final prospectus

EDGAR filings resolved from KLRA / CIK 0002096997.

424B4424B4
Apr 17, 2026Final prospectus0001193125-26-161521
8-A12B8-A12B
Apr 14, 2026Exchange registration0001193125-26-154882
S-1/AS-1/A
Apr 13, 2026Amended0001193125-26-151904
S-1S-1
Mar 27, 2026Filed0001193125-26-128952
DRS/Afilename1.htm
Feb 11, 2026Confidential draft0001193125-26-046566
DRSfilename1.htm
Dec 19, 2025Confidential draft0001193125-25-326849

Kailera Therapeutics Inc IPO — frequently asked questions

When did Kailera Therapeutics Inc go public?
Kailera Therapeutics Inc completed its IPO on Apr 17, 2026 on NASDAQ Global Select under the ticker KLRA and now trades publicly.
What was Kailera Therapeutics Inc's IPO price?
Kailera Therapeutics Inc priced its IPO at $16.00 per share.
Can I buy Kailera Therapeutics Inc stock?
Yes — Kailera Therapeutics Inc is publicly traded on NASDAQ Global Select as KLRA. You can follow its live price, valuation and post-IPO performance above.
What is Kailera Therapeutics Inc's valuation?
Kailera Therapeutics Inc's most recent valuation tracked here is $2.44B, derived from live market prices.